CLICK HERE if you are a Consumer

Patient Satisfaction




‡ Calculations based on average wholesale price, assuming 0.5 g/application(s) per day for 30 days.
§ At week 15, stinging and burning scores were comparable.
Line 2: Cost for 30-day supply
Line 3: Formulary coverage (tier 2)
Line 4: Significant reduction in inflammatory lesions
Line 5: Significant change in erythema scores from baseline at week 15
Line 6: Pregnancy category B
Line 7: HSA-3 vehicle
Line 9: Significantly bothered by drug side effects
Line 10: Significantly higher incidence of stinging
and burning at week 3
Line 11: Potential for hypopigmentation

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

Important Safety Information

MetroGel® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea. MetroGel® 1% gel is contraindicated in individuals with a history of hypersensitivity to metronidazole or any other ingredients in this formulation. For more information about MetroGel®, see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.